Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aquestive Therapeutics Inc
(NQ:
AQST
)
4.460
+0.150 (+3.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
742,976
Open
4.380
Bid (Size)
4.430 (1)
Ask (Size)
4.550 (10)
Prev. Close
4.310
Today's Range
4.320 - 4.550
52wk Range
1.251 - 6.230
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 22, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
August 14, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+121.89%
+121.89%
1 Month
+29.28%
+29.28%
3 Month
+43.87%
+43.87%
6 Month
+56.49%
+56.49%
1 Year
+149.16%
+149.16%
More News
Read More
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
July 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
July 23, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
June 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
June 25, 2024
Via
Benzinga
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
June 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
June 18, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
June 03, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
May 28, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
April 29, 2024
Via
Benzinga
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
April 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
April 18, 2024
Via
Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
April 17, 2024
Via
InvestorPlace
Exposures
Product Safety
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
April 12, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 04, 2024
Via
Benzinga
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
April 04, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
April 01, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
March 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Dow Surges 350 Points; Fed Holds Rates Steady
March 20, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.